Dr Nancy Richert joined Biogen as a Senior Fellow in MS Clinical Development in 2010. Her role at Biogen has been designing MRI outcome measures for clinical trials, and early MRI detection of PML in Natalizumab-treated patients. She has recently joined the Value Based Medicine team (VBM) at Biogen, which is focusing on using new technology to develop innovative tools to better understand, measure and manage the treatment of MS Prior to this, Dr Richert was a Staff Clinician in Neuroimmunology at the National Institute of Neurological Disorders and Stroke (NINDS) within the National Institutes of Health (NIH) and a Consultant in Diagnostic Imaging and Radiology at Children’s National Medical Centre in Washington DC. In addition Dr Richert has served as a Member of the National MS Society’s (NMSS) Scientific Peer Review Committee (2003 – 2007). She was also a member of the NMSS Task Force for Nervous System Repair and is currently a member of the NMSS task force for progressive MS. Dr Richert’s primary specialty is in imaging in MS including magnetic resonance imaging (MRI) and magnetisation transfer ratios (MTR). Over the past 14 years her work has advanced the development and application of MRI outcome measures of disease activity in MS. Dr Richert’s work in clinical trials includes measurements and predictors of brain atrophy. She has participated in several clinical trials for interferonβ-1b, Insulin-like growth factor, altered peptide ligand, and most recently daclizumab. Dr Richert has had been a scientific and medical reviewer for journals including Neurology, Multiple Sclerosis and Annals of Neurology and ad hoc reviewer for the National MS Society, Canadian and Australian MS societies.